Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Monday 31 March, 2008


Les r�sultats de l'�tude Phase II de CDP791 pou...

Les r�sultats d�montrent l'activit� biologique de CDP791. Une
�volution positive a �t� observ�e sur plusieurs des crit�res
d'efficacit� test�s. Ces donn�es encourageantes incitent la poursuite
du d�veloppement clinique de CDP791 pour le traitement en premi�re
ligne du cancer du "poumon non � petites cellules".  UCB �value des
pistes de partenariat.

Bruxelles (Belgique) - le 31 mars 2008 - 7 heures (CET) -
Aujourd'hui, UCB publie les premiers r�sultats de son �tude
d'�valuation de Phase II de CDP791, un inhibiteur sp�cifique de
VEGFR-2/KDR, en association avec une chimioth�rapie au carboplatine
et au paclitaxel, pour le traitement de premi�re ligne du cancer du
"poumon non � petites cellules" (NAPC). Des am�liorations ont �t�
observ�es sur plusieurs crit�res d'efficacit�, y compris le taux de
r�ponse tumorale et le d�lai avant progression tumorale. Ces
r�sultats incitent la poursuite du d�veloppement clinique pour le
traitement en premi�re ligne du cancer du poumon NAPC. UCB s'att�le �
mettre en place les programmes de d�veloppement cliniques ult�rieurs
et �value des pistes de partenariat.

Le crit�re d'efficacit� primaire a port� sur le taux de r�ponse
tumorale �valu� au cours d'une analyse ind�pendante. Un accroissement
de 17,7% du taux de r�ponse tumorale a �t� observ� pour la dose la
plus �lev�e de CDP791 (20 mg/kg) en association avec la
chimioth�rapie (37,7%) compar� au traitement par chimioth�rapie seule

Le risque de progression tumorale a �t� r�duit de 32% chez les
patients ayant re�u une dose de 20 mg/kg de CDP791 associ�e � la
chimioth�rapie compar� � la chimioth�rapie seule. Les patients ayant
re�u une dose de 20 mg/kg de CDP791 associ�e � la chimioth�rapie
pr�sentent un d�lai m�dian avant progression tumorale de 30,1
semaines, contre 27,3 semaines pour les patients trait�s par
chimioth�rapie uniquement. Bien que le taux de survie sans
progression n'ait pas d�montr� d'effet th�rapeutique dans cet essai
de Phase II, l'analyse pr�liminaire de la survie globale est
suffisamment encourageante pour motiver la poursuite du d�veloppement
de la mol�cule.

A propos de la m�thodologie d'essai
Cet essai multicentrique a �t� r�alis� en deux temps chez des
patients atteints d'un cancer du poumon NAPC � un stade localement
avanc� ou m�tastas� (stade IIIb ou stade IV).  Dans la premi�re
phase, la tol�rabilit� de CDP791 dos� � 10 mg/kg et 20mg/kg associ� �
une chimioth�rapie standard � base de carboplatine et de paclitaxel a
�t� �valu�e chez deux cohortes de patients.  Les deux dosages ont �t�
bien tol�r�s.
Dans la seconde phase, 156 patients ont �t� r�partis de mani�re
al�atoire en trois groupes th�rapeutiques : CDP791 � 20 mg/kg avec
chimioth�rapie, CDP791 10 mg/kg avec chimioth�rapie ou chimioth�rapie
isol�e en 6 s�ances.  Ensuite, les patients �ligibles sont pass�s au
traitement CDP791 seul.  Un comit� ind�pendant de contr�le des
donn�es a �valu� les donn�es d'innocuit� transitoires et les donn�es
d'efficacit� �mergentes.

A propos de CDP791
CDP791 est un fragment di-Fab humanis� p�gyl� qui inhibe
sp�cifiquement l'activation de VEGFR-2 par ses ligands VEGF-A,
VEGF-C, VEGF-D.  CDP791 �tant exempt de Fc, son activit� est
enti�rement due � sa puissante action bloquante.  CDP791 se lie
sp�cifiquement � VEGFR-2 et inhibe les signaux transmis par son
r�cepteur.  Ce m�canisme diff�re de celui des inhibiteurs de VEGF sur
le march� et constitue un nouvel angle d'attaque de la voie VEGF.
VEGFR-2 est un facteur essentiel de l'angiog�n�se, qui intervient
dans la formation de nouveaux vaisseaux sanguins favorisant la
croissance tumorale.
Il a �t� d�montr� que CDP791 inhibait fortement la liaison de VEGF �
VEGFR-2 in vitro et emp�chait l'angiog�n�se dans des mod�les

Cancer du poumon non � petites cellules (CPNAPC)
Selon l'OMS, on recense chaque ann�e plus de 1,2 million de cas de
cancers pulmonaires et bronchiques, � l'origine de 1,1 million de
d�c�s annuels.  Le CPNAPC est la forme la plus fr�quente de la
maladie et repr�sente environ 80 � 85% des cancers du poumon.

Pour toutes questions, veuillez contacter
Antje Witte, Vice-President Corporate Communications & Investor
Relations, UCB Group
T +32.2.559.9414, [email protected]

A propos d'UCB
UCB ( est un laboratoire biopharmaceutique mondial
qui se concentre sur la recherche, le d�veloppement et la
commercialisation de produits pharmaceutiques et biotechnologiques
innovants li�s aux troubles du syst�me nerveux central (y compris
l'�pilepsie), aux troubles immunitaires et inflammatoires (y compris
les affections allergiques/respiratoires) et au domaine de
l'oncologie. UCB vise � asseoir sa position de leader dans le
traitement de maladies graves. La soci�t� emploie environ 12 000
personnes r�parties dans plus de 40 pays et a enregistr� un chiffre
d'affaires de 3,6 milliards d'euros en 2007. UCB est cot�e sur
Euronext Brussels.


a d v e r t i s e m e n t